Initiation, Continuation, or Withdrawal of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction

Author:

Gilstrap Lauren G.1,Fonarow Gregg C.2,Desai Akshay S.1,Liang Li3,Matsouaka Roland3,DeVore Adam D.3,Smith Eric E.4,Heidenreich Paul5,Hernandez Adrian F.3,Yancy Clyde W.6,Bhatt Deepak L.1

Affiliation:

1. Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA

2. Ahmanson‐UCLA Cardiomyopathy Center, Ronald Reagan‐UCLA Medical Center, Los Angeles, CA

3. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC

4. Department of Clinical Neurosciences, University of Calgary, Alberta, Canada

5. Veterans Affairs Palo Alto Health Care System, Palo Alto, CA

6. Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL

Abstract

Background Guidelines recommend continuation or initiation of guideline‐directed medical therapy, including angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers ( ACE i/ ARB ), in hospitalized patients with heart failure with reduced ejection fraction. Methods and Results Using the Get With The Guidelines‐Heart Failure Registry, we linked clinical data from 16 052 heart failure with reduced ejection fraction (ejection fraction ≤40%) patients with Medicare claims data. We divided ACE i/ ARB ‐eligible patients into 4 categories based on admission and discharge ACE i/ ARB use: continued (reference group), started, discontinued, or not started on therapy. A multivariable Cox proportional hazard model was used to determine the association between ACE i/ ARB category and outcomes. Most, 90.5%, were discharged on ACE i/ ARB (59.6% continued and 30.9% newly started). Of those discharged without ACE i/ ARB , 1.9% were discontinued, and 7.5% were eligible but not started. Thirty‐day mortality was 3.5% for patients continued and 4.1% for patients started on ACE i/ ARB . In contrast, 30‐day mortality was 8.8% for patients discontinued (adjusted hazard ratio [ HR adj ] 1.92; 95% CI 1.32‐2.81; P <0.001) and 7.5% for patients not started ( HR adj 1.50; 95% CI 1.12‐2.00; P =0.006). The 30‐day readmission rate was lowest among patients continued or started on therapy. One‐year mortality was 28.2% for patients continued and 29.7% for patients started on ACE i/ ARB compared to 41.6% for patients discontinued ( HR adj 1.35; 95% CI 1.13‐1.61; P <0.001) and 41.7% ( HR adj 1.28; 95% CI 1.14‐1.43; P <0.001) for patients not started on therapy. Conclusions Compared with continuation, withdrawal of ACE i/ ARB during heart failure hospitalization is associated with higher rates of postdischarge mortality and readmission, even after adjustment for severity of illness.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3